Critical

Anti-MDA5 dermatomyositis with rapidly progressive ILD

Amyopathic DM, fulminant lung disease · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Anti-MDA5 antibody-positive dermatomyositis is frequently clinically amyopathic but carries a high risk of rapidly progressive interstitial lung disease with very high mortality. Cutaneous ulceration, palmar papules and minimal muscle weakness with acute hypoxaemic respiratory failure are characteristic.

Red flags

  • Rapidly rising oxygen requirement
  • Ferritin >1500-3000 micrograms/L and rising
  • Extensive/worsening ground-glass or consolidation on HRCT
  • Cutaneous ulceration (poor prognostic sign)
  • Pneumomediastinum

Assessment

Differential diagnosis

  • Antisynthetase syndrome
  • Acute interstitial pneumonia / ARDS
  • Severe infective pneumonia (incl. opportunistic)
  • Other CTD-associated ILD
  • Diffuse alveolar haemorrhage
  • Hypersensitivity pneumonitis

Investigations

  • Myositis antibody panel including anti-MDA5 (anti-CADM-140)
  • Serum ferritin (very high predicts poor prognosis)
  • High-resolution CT chest and serial lung function / transfer factor
  • ABG and continuous oxygen saturation monitoring
  • CK (often normal/mildly raised), LDH, KL-6 where available
  • Infection screen including PJP and respiratory viral PCR

Management

  • Recognise the high-risk phenotype: DM skin signs, little weakness, rising ferritin, falling oxygenation
  • Admit to HDU/ICU early and provide oxygen / ventilatory support
  • Exclude and empirically cover infection (including PJP)
  • Start aggressive triple immunosuppression without delay - delay worsens survival
  • Combine high-dose corticosteroid, a calcineurin inhibitor and cyclophosphamide/rituximab
  • Consider plasma exchange or JAK inhibitor in refractory rapidly progressive disease per specialist advice
  • Monitor serial ferritin, oxygenation and HRCT as prognostic markers
  • Discuss early with ILD/transplant and ICU teams given high mortality

Drugs & doses

Methylprednisolone — 1 g IV OD for 3 days then prednisolone 1 mg/kg/day
Tacrolimus — 0.075 mg/kg/day PO, adjusted to trough 5-10 micrograms/L
Cyclophosphamide — 500-1000 mg/m2 IV monthly (dose-adjusted)
Tofacitinib — 5 mg PO BD (emerging option in refractory anti-MDA5 RP-ILD)
Co-trimoxazole — 480-960 mg PO OD for PJP prophylaxis with intensive immunosuppression

Disposition

Admit to ICU/HDU; immediate triple immunosuppression with combined rheumatology, respiratory and intensive care input.

Complications & pitfalls

  • Fatal rapidly progressive respiratory failure
  • Pneumomediastinum / pneumothorax
  • Superimposed opportunistic infection
  • Multi-organ failure
  • Treatment-related toxicity

Exam pearls

  • Among the highest-mortality rheumatological lung presentations - aggressive early combination therapy improves survival
  • Ferritin level tracks disease activity and prognosis
  • Muscle enzymes may be normal (clinically amyopathic) - do not be falsely reassured
  • Spontaneous pneumomediastinum is a recognised ominous feature

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.